


 Cite this: *RSC Adv.*, 2023, **13**, 24250

A novel series of dipeptide derivatives containing indole-3-carboxylic acid conjugates as potential antimicrobial agents: the design, solid phase peptide synthesis, *in vitro* biological evaluation, and molecular docking study†

 Sunil R. Tivari,^{‡a} Siddhant V. Kokate,^{‡b} Enrique Delgado-Alvarado,^{cd} Manoj S. Gayke,^e Amol Kotmale,^f Harun Patel,^g Iqrar Ahmad,^g Elizabeth M. Sobhia,^h Siva G. Kumar,ⁱ Bianey García Lara,^b Vicky D. Jain^a and Yashwantsinh Jadeja ^{*a}

A new library of peptide-heterocycle hybrids consisting of an indole-3-carboxylic acid constituent conjugated with short dipeptide motifs was designed and synthesized by using the solid phase peptide synthesis methodology. All the synthesized compounds were characterized by spectroscopic techniques. Additionally, the synthesized compounds were subjected to *in vitro* antimicrobial activities. Two Gram-negative bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*) and two Gram-positive (*Streptococcus pyogenes* and *Staphylococcus aureus*) were used for the evaluation of the antibacterial activity of the targeted dipeptide derivatives. Good antibacterial activity was observed for the screened analogues by comparing their activities with that of ciprofloxacin, the standard drug. Also, two fungi (*Aspergillus niger* and *Candida albicans*) were employed for the evaluation of the antifungal activity of the synthesized compounds. When compared to the standard drug Fluconazole, it was observed that the screened analogues exhibited good antifungal activity. In continuation, all the synthesized derivatives were subjected to integrated molecular docking studies and molecular dynamics simulations to investigate binding affinities, intermolecular interaction networks, and conformational flexibilities with deoxyribonucleic acid (DNA) gyrase and lanosterol-14- α demethylase. The molecular docking studies revealed that indole-3-carboxylic acid conjugates exhibited encouraging binding interaction networks and binding affinity with DNA gyrase and lanosterol-14 α demethylase to show antibacterial and antifungal activity, respectively. Such synthesis, biological activity, molecular dynamics simulations, and molecular docking studies of short peptides with an indole conjugate unlock the door for the near future advancement of novel medicines containing peptide-heterocycle hybrids with the ability to be effective as antimicrobial agents.

Received 18th June 2023

Accepted 23rd July 2023

DOI: 10.1039/d3ra04100j

rsc.li/rsc-advances

1 Introduction

As the 21st century unfolds, antimicrobial resistance (AMR) poses a grave threat to the health of mankind. The term antimicrobial therapeutics refers to therapeutics that fight

infections caused by fungi, bacteria, viruses, *etc.*^{1,2} The development of AMR to antibiotics occurs whenever a pathogen develops resistance to them and certain developments in pathogens make medicines less potent at curing diseases. The AMR can happen naturally throughout the course of evolution.

^aDepartment of Chemistry, Marwadi University, Rajkot-360003, Gujarat, India. E-mail: drysjadeja@gmail.com

^bDepartamento de Química, Universidad de Guanajuato, Noria Alta S/N, Guanajuato-36050, Guanajuato, Mexico

^cMicro and Nanotechnology Research Center, Universidad Veracruzana, Blvd. Av. Ruiz Cortines No. 455 Fracc. Costa Verde, Boca del Río 94294, Mexico

^dFacultad de Ciencias Químicas, Universidad Veracruzana, Blvd. Av. Ruiz Cortines No. 455 Fracc. Costa Verde, Boca del Río 94294, Mexico

^eIndrashil University, Rajpur, Kadi, Mehsana 382740, Gujarat, India

^fDepartment of Chemistry, Savitribai Phule Pune University, Pune 411007, Maharashtra, India

^gDepartment of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur District, Dhule 425405, Maharashtra, India

^hDepartment of Pharmacoinformatics, NIPER, Mohali 160062, Punjab, India

ⁱDepartment of Medicinal Chemistry, Sri Venkateswara College of Pharmacy, Chittoor 517127, Andhra Pradesh, India

 † Electronic supplementary information (ESI) available: Spectral data of all newly synthesized compounds along with methods for their biological activities. See DOI: <https://doi.org/10.1039/d3ra04100j>

‡ Both authors have equal contributions.



However, the misuse or overuse of medicines can hasten the process of AMR. Whenever an ill individual consumes the wrong medication or takes it incorrectly, the pathogen that leads to the illness withstands the exposure to the medicine that normally kills it or hinders its growth. Then that survived pathogen can propagate causing an upsurge in the number of pathogens, which are resistant to medication. This in turn leads to an increase in the number of diseases that are resistant to that particular medication. Therefore, if the rise in resistance to antimicrobial therapeutics is not controlled, many pathogens could become extremely life threatening. The resistance to antimicrobial therapeutics may cause 10 million deaths annually by the year 2050, according to a report released by the government of the United Kingdom.³ World health organization and experts around the world concurred that the surge in resistance to antimicrobial therapeutics is a critical issue requiring an immediate and concerted global action plan.^{4,5} Therefore, efforts to discover novel therapeutics that can be utilized as potent antimicrobial medicines are crucial for the future to evade this AMR.^{6,7}

Antimicrobial peptides (AMPs) have demonstrated good capability to prevent AMR, which has rendered many therapeutics ineffective.⁸ AMPs have shown a broad spectrum of antimicrobial characteristics when tested against a diverse range of pathogens.^{9–11} Lots of peptides with antimicrobial properties are effective against pathogens that are resistant towards many medications and have a very low tendency to achieve resistance. Peptides with antimicrobial properties are seen as promising and viable therapeutic prospects for the coming future because of their lesser toxicity, a wide range of activities, and depleted resistance. Numerous different types of organisms are capable of producing AMPs, commonly referred to as host defence peptides, which are extremely vital parts of their inherent immune system. Even though predominantly AMPs with cationic motifs are seen,^{12–14} the anionic motif of AMPs has also been reported.^{15,16} The three most universal structural characteristics of AMPs consist of their relatively smaller peptide sequence (often 12–50 amino acids), cationic character (owing to the inclusion of one or more arginine, lysin, and/or histidine), and amphipathic motif (both hydrophobic and hydrophilic characteristics are observed in it). Numerous studies have demonstrated the importance of the net separation of hydrophobic and hydrophilic sections as well as the peptide's net charge.^{17,18} A sudden rise in bacterial resistance is observed when traditional antibiotics mark specific receptors. Peptides with antimicrobial properties have different modes of action than this. The mechanism of action involves either disruption of the stability of bacterial membranes or the important internal cell units of bacteria.^{19,20} The membrane lytic action is one of the main advantages of AMPs, which has long been believed that is unaffected by the mechanism of action underlying resistance to antibiotics.²¹ Despite the fact that AMPs have many benefits, there are several obstacles to their profitable commercial and therapeutic expansion as medicines. The most significant downside in the use of AMPs as therapeutics lies in their inability to be administered orally owing to the ease with which gastrointestinal enzymes could inactivate AMPs.^{22,23} AMPs

are susceptible to protease and their synthesis cost is huge, these two additional drawbacks make the application of AMPs as therapeutics challenging. With the goal to boost stability against protease and oral bioavailability, many ground-breaking studies have been conducted that consists of the design and synthesis of short peptides from long series of natural AMPs while maintaining integral properties of natural AMPs, such as their net cationic peptide charge and the amphipathic motif.^{24–27}

Worldwide, the synthetic route of peptides using solid support (solid phase peptide synthesis or SPPS) is usually favoured by researchers for the synthesis of AMPs over the synthetic route of peptides using liquid phase (liquid phase peptide synthesis or LPPS), particularly for peptides with long sequences. The SPPS route is much more effective than the conventional LPPS route because it is exceptionally efficient, utilizes straightforward synthetic processes and simple purification methods, rapidly synthesizes linear peptides, and produces products with high purity. Additionally, unlike LPPS, in SPPS there is no need for isolation of the prepared intermediates or high-speed procedures. SPPS route can be used for the synthesis of any sort of peptide sequence, such as short-long chain, complex, or cyclic. Some of the most compelling features of the SPPS protocol are that the peptide synthesis can be fully automated, and its scalability can be drastically improved by using an automated peptide synthesizer.²⁸

Scientists all over the globe are highly interested in the research and development of novel therapeutics containing heterocyclic scaffolds due to the fact that, in nature, heterocyclics are omnipresent and have a wide range of synthetic applications and biological activities.^{29–33} Among all the available heterocyclic analogues nitrogen-containing heterocycles are the amplest and have great biological applicability than those containing oxygen and sulphur.^{34–36} For medicinal chemists to obtain novel potent therapeutics, indole which is also known as benzopyrrole, an aromatic heterocyclic compound containing a nitrogen atom, is of great significance. Derivatives of indole have plenty of notable biological activities like antiviral,³⁷ anticancer,³⁸ anti-inflammatory and analgesic,³⁹ anti-HIV,⁴⁰ antioxidant,⁴¹ antimicrobial,⁴² antituberculosis,⁴³ *etc.* Indole is one of the most important and widely used conjugate of the heterocyclic family. In the pharmaceutical market, plenty of drugs are available with indole moieties, like, Ondansetron,⁴⁴ Alosetron,⁴⁵ Indomethacin,⁴⁶ Yohimbine,⁴⁷ *etc.*

Considering the aforementioned facts, we designed and synthesized a novel library of hybrids of peptide-heterocycle (short dipeptides) consisting of indole-3-carboxylic acid constituent at the N-terminus and tyrosine at the C-terminus by employing the protocol of SPPS (Fig. 1). Additionally, we evaluated the antimicrobial activities of the obtained hybrids. The observed activities were compared to Ciprofloxacin, a standard drug, (for antibacterial activities) and Fluconazole, a standard drug, (for antifungal activities). Moreover, we have performed molecular docking studies on the short peptide derivatives that we have synthesized. The obtained dipeptide derivatives using this methodology involved effortless purification stages and the obtained intermediates during the synthesis of the required






Fig. 1 Peptide library of title compounds 6a–j.

dipeptides do not require isolation. The combination of experiential and *in silico* studies of prepared derivatives 6a–j would aid to establish the harmless and effective therapeutics to address the AMR.

2 Material and methods

The 2-chlorotrityl chloride (2-CTC) resin was utilized for the synthesis of a series of short peptide derivatives with indole-3-carboxylic acid constituent. Highly efficient loading estimation is obtained from using such resin. This resin is mainly used for the synthesis of short-chain peptides.⁴⁸ It was purchased from Merck. Fmoc (9-fluorenylmethoxycarbonyl)-protected L-amino acids were utilized and acquired from Sichuan, China. HBTU (2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium) and triisopropylsilane (TIS) were acquired from survival chemical. HOBt·H₂O (*N*-hydroxybenzotriazole monohydrate), diisopropylethylamine (DIPEA) and trifluoroacetic acid (TFA) acquired from Spectrochem. Phenol acquired from SD fine chemicals. A fully automated CSBio peptide synthesizer (CS136X) was utilized for the synthesis of derivatives.

An open capillary method was utilized to determine the melting points which were uncorrected. The Kaiser test was used for monitoring the deprotection and coupling reactions. A mixture of ethyl acetate and *n*-hexanes was used for the purification of the derivatives. Nicolet impact 400 Fourier-transform infrared (FTIR) spectrometer was employed to determine the IR spectra and potassium bromide (KBr) pressed pellet technique was used for that purpose. Shimadzu liquid chromatography mass spectrometry (LC-MS) (at 70 eV) Mass Spectrometer

(ESI) was used to determine the mass spectra. Bruker Avance 400 MHz NMR (nuclear magnetic resonance) spectrometer was used to determine the ¹H and ¹³C NMR spectra using DMSO-*d*₆ (deuterated dimethyl sulfoxide) solvent.

3 Experimental section

3.1 Synthetic route for the formation of intermediate 1

To the peptide synthesizer, the 2-CTC resin was added. The substitution of the resin was 1.0 mmol g⁻¹. Then the resin was washed with dichloromethane (DCM; 10 volumes (v)) and drained. Then, DCM (10 volumes) was added, stirred the reaction mass for 60 minutes (swelling), and drained. The Fmoc-Tyr(*t*Bu)-OH (3.0 equiv.) was dissolved in DCM and transferred into the reaction vessel. Further, added DIPEA (6 equiv.) into the reaction vessel and stirred at 25 °C for 2 h. The peptidyl resin was filtered after 2 h and washed two times with DCM and one time with dimethylformamide (DMF).⁴⁹ A solution of DIPEA, methanol (MeOH), and DCM (1 : 2 : 8) was utilized to cap the unreacted functional groups of resin. The ultraviolet (UV) spectrophotometer was used for monitoring the loading percentage.

3.2 Synthetic route for the formation of intermediates 5a–j

Standard Fmoc/*t*-Bu(*t*-butyl)/Boc(*t*-butyloxycarbonyl) protocol was utilized to obtain the desired intermediates 5a–j using the SPPS method. In the SPPS reaction vessel, swelling of Fmoc-Tyr(*O**t*-Bu)-2-CTC resin was carried out in 20 volumes of DMF (with respect to the initial weight of the resin) for half an hour. CSBio peptide synthesizer was used for the synthesis of the



desired intermediates. After swelling, desired intermediates were synthesized by repeating the subsequent steps: (a) deprotection of the Fmoc group was performed by utilizing 20% of piperidine/DMF (v/v) (10 volumes). The resin was washed two times (5 min and 10 min washings). Kaiser test was employed to check the complete deprotection. The blue colour of the test solution confirmed the complete deprotection. After this step, the reaction mass (peptidyl resin) was filtered and washed two times with DMF, one time with isopropyl alcohol (IPA), and three times with DMF. (b) Fmoc amino acid (3.0 equiv., 3 mmol with respect to the initial resin loading), HBTU (3.0 equiv., 3 mmol), HOBT·H₂O (3.0 equiv., 3 mmol), and DIPEA (6.0 equiv., 6 mmol) in 6 volumes of DMF was used for all the coupling reactions. One hour of stirring time was required for all the coupling reactions. Kaiser test was employed to check the completion of the reaction. Colourless test solution and beads were detected in the test, which verified the completion of the coupling step.⁵⁰ After this step, the reaction mass (peptidyl resin) was filtered and washed five times with DMF.

3.3 Synthetic route for the synthesis of desired derivatives 6a-j

A mixture of TFA : TIS : H₂O (80 : 10 : 10) (10 mL g⁻¹) was used as a cleavage cocktail for the side chain and CTC resin cleavage. The protected peptidyl resin was stirred in the cleavage cocktail for 3 h at 20–25 °C.⁵¹ After 3 h, the reaction mass was filtered,


and the obtained filtrate was precipitated using diisopropyl ether (DIPE) (50 v). Then the reaction mass was filtered and washed three times with DIPE (10 v). Dried the wet cake at 30 °C under a vacuum to get the desired products.

4 Results and discussion

4.1 Chemistry

As noted from Scheme 1, a new library of hybrids of peptide-heterocycle consisting of indole-3-carboxylic acid constituent conjugated with short dipeptide motifs **6a-j** were designed and synthesized by using the methodology of SPPS *via* HBTU/HOBT coupling protocol. Yields of novel derivatives were in the range of 89–92%. All synthesized peptide derivatives were obtained in the form of solid powder and showed excellent physical stability.

The synthesis of dipeptide derivatives consisting of indole moiety **6a-j** utilizing the 2-CTC resin is illustrated in Scheme 1. It involves repetitive cycles of coupling and deprotection. The 1st step is the formation of Fmoc-Tyr-2-CTC resin **1**. It was obtained by loading Fmoc-Tyr-OH on 2-CTC resin by using DIPEA in DCM. 20% piperidine in DMF was utilized to deprotect the Fmoc group from **1** to give H₂N-Tyr-2-CTC resin **2**, having the free –NH₂ (amino) functionality at N-terminal. The presence of free –NH₂ functionality and thus complete deprotection were confirmed by carrying out the Kaiser test. The complete deprotection was confirmed when a blue coloured test solution



Scheme 1 Route of synthesis of indole dipeptide derivatives **6a-j**.



was observed. Further, coupling of different Fmoc protected amino acids, Fmoc-R(SPG)-OH, with **2** was carried out employing coupling reaction conditions involving HBTU/HOBt. This step yielded Fmoc-R(SPG)-Tyr-2-CTC resin **3a-j**, here, 'SPG' is a side chain protecting group and 'R' is a different amino acid. Completion of the coupling reaction is monitored by the Kaiser test. The test solution and beads were colourless, which concluded the success of the coupling reaction. Further, the deprotection of the Fmoc group of **3a-j** yielded H₂N-R(SPG)-Tyr-2-CTC resin **4a-j**. Here also, the Kaiser test was used to validate the complete deprotection of the Fmoc group. Coupling of **4a-j** with indole (N-Boc)3-carboxylic acid by employing above mentioned HBTU/HOBt coupling reaction conditions yielded indole (N-Boc)3-R(SPG)-Tyr-2-CTC resin moieties **5a-j**. The global cleavage of **5a-j** for three hours at room temperature is the final step in the Scheme 1. It uses the cleavage cocktail of TIS:H₂O:TFA in the ratio 10:10:80. DIPE was used for precipitation to give the required dipeptides with indole conjugates. CTC resin and SPGs were cleaved from the desired peptide sequence by this final step – "acidolysis". Ethyl acetate and *n*-hexanes were used for further purification of crude to obtain the pure form of desired compounds **6a-j** in 89–92% yields.

The IR analysis of **6a** was carried out to determine its structure, which exhibited the typical absorption bands at 3500–3200, 1700–1500, and 3600–2500 cm⁻¹ for –NH, –CONH–, and –COOH stretching, respectively. In general, the ¹H NMR spectrum of compound **6a** showed 13 aromatic protons between 6.5 and 9 δ ppm, whereas 6 aliphatic protons were distributed between 3 and 5 δ ppm. Mass spectrometry data of **6a** was found to be 462.28 [M + 1]⁺, which also confirmed the formation of the peptide conjugate **6a**. Similarly, the rest of the derivatives have been characterized, and their characterization data is given in the ESI file.†

4.2 Biological evaluation

The organisms, *Escherichia coli* MTCC 443 and *Pseudomonas aeruginosa* MTCC 1688, *Streptococcus pyogenes* MTCC 442 and *Staphylococcus aureus* MTCC 96, *Aspergillus niger* MTCC 282 and *Candida albicans* MTCC 227 were collected from King Abdullah University Hospital (KAUH), Irbid, Jordan and were stored at –70 °C in trypticase-soy broth with 20% glycerol form BBL Microbiology Systems (Cockeysville, Md, USA) until ready for batch susceptibility testing. They were thawed and passed 3 times to assure purity and viability. The conventional Mueller–Hinton Broth-microdilution method was utilized to study the *in vitro* antimicrobial activities of the synthesized compounds **6a-j**.⁵² It is a quantitative antimicrobial susceptibility testing method and is used to determine the minimum inhibitory concentration (MIC) of antimicrobial agents. In this test, under *in vitro* conditions, microorganisms are screened for their capability to produce visible growth in broth (broth dilution) consisting different dilutions of the antimicrobial agents. MIC value is the lowest concentration of an antimicrobial agent at which the visible growth of a microorganism is prohibited within a definite period of time. When compared to macrobroth

dilution method, microbroth dilution method shows many advantages, like miniaturization and mechanization due to utilization of disposable small plastic "microdilution" trays. Additionally, advantages like reproducibility, prepared panels, cheap reagents and space that resulted owing to its miniaturization makes Mueller–Hinton Broth-microdilution method practical and popular among the research across the world.^{53,54}

The procedures used for the antimicrobial assay were:

4.2.1 Antibacterial activity assay. The strains used were newly procured and stored under appropriate conditions. The compounds were screened for their antibacterial activity in triplicates against the bacteria at different concentrations of 1000, 500, 250, and 200 μg mL⁻¹. The compounds which were found to be effective in inhibition were further diluted and tested. The Mueller–Hinton Broth dilution method was used for the antibacterial assay. 10 μg mL⁻¹ suspension of respective bacteria was inoculated on appropriate media and growth was noted after incubation at 37 °C for a period of one or two days. The test mixture should contain 10⁸ cells per mL. In this study, ciprofloxacin was used as a standard drug for evaluating the antibacterial activity.⁵²

4.2.2 Antifungal activity assay. The strains used were newly procured and stored under appropriate conditions. The compounds were screened for their antifungal activity in triplicates against the fungi at different concentrations of 1000, 500, 250, and 200 μg mL⁻¹. The compounds which were found to be effective in inhibition were further diluted and tested. The Muller–Hinton Broth dilution method was used for the antifungal assay. In this study, for fungal growth, Sabouraud's dextrose broth was used at 28 °C in aerobic conditions for 48 hours. Fluconazole was used as a standard for comparison purposes.⁵²

Source of drugs obtained from Marwadi University, Gujarat. The findings of the biological evaluation of peptide derivatives

Table 1 Antibacterial and antifungal activities of the synthetic derivatives **6a-j**^a

Entry	Name of derivative	MIC (antibacterial activity) in μg mL ⁻¹				MIC (antifungal activity) in μg mL ⁻¹	
		E. C.	P. A.	S. A.	S. P.	C. A.	A. N.
6a	Indole-His-Tyr-OH	25	125	150	90	80	70
6b	Indole-Gly-Tyr-OH	250	250	500	500	500	>1000
6c	Indole-Asp-Tyr-OH	125	200	250	250	500	500
6d	Indole-Ser-Tyr-OH	25	125	200	250	100	50
6e	Indole-Phe-Tyr-OH	200	200	500	500	500	500
6f	Indole-Glu-Tyr-OH	125	200	250	250	500	500
6g	Indole-Met-Tyr-OH	12.5	80	200	125	50	80
6h	Indole-Asn-Tyr-OH	125	200	250	250	500	500
6i	Indole-Thr-Tyr-OH	25	125	200	250	50	80
6j	Indole-Ile-Tyr-OH	500	500	500	500	>1000	>1000
Std-1	Ciprofloxacin	15	50	25	50	—	—
Std-2	Fluconazole	—	—	—	—	50	50

^a E. C.: *Escherichia coli*, P. A.: *Pseudomonas aeruginosa*, S. A.: *Staphylococcus aureus*, S. P.: *Streptococcus pyogenes*, C. A.: *Candida albicans*, A. N.: *Aspergillus niger*.



6a–j versus bacterial and fungal strains show that compared to other strains the synthesized novel derivatives are most active against the bacterial strain *E. coli* (Table 1).

The peptide conjugate **6g** was found to be 8 times more potent against *E. coli* with a MIC value of $12.5 \mu\text{g mL}^{-1}$ as compared with standard Ciprofloxacin which had a MIC of $15 \mu\text{g mL}^{-1}$. Indole dipeptide conjugates **6a**, **6d**, and **6i** had MIC values of $25 \mu\text{g mL}^{-1}$ and were 4 times more potent than the control drug. Other conjugates **6c**, **6f**, and **6h** were slightly less active than the standard Ciprofloxacin with a MIC value of $25 \mu\text{g mL}^{-1}$ against the bacterial strain *E. coli*. Against *P. aeruginosa*, apart from **6g**, the activity of indole dipeptide conjugates was found to be less as compared to the control drug. Conjugate **6g** exhibited a MIC value of $80 \mu\text{g mL}^{-1}$, whereas **6a**, **6d**, and **6i** were active at a MIC value of $125 \mu\text{g mL}^{-1}$ against the bacterial strain *P. aeruginosa*. Similarly, peptide conjugate **6a**, **6d**, **6g**, and **6i** were more active than the standard drug, as **6a** inhibited the *Staphylococcus aureus* at a MIC value of $150 \mu\text{g mL}^{-1}$ and **6d**, **6g**, and **6i** exhibited inhibition at $200 \mu\text{g mL}^{-1}$, whereas the control drug inhibited the bacterial strain at $25 \mu\text{g mL}^{-1}$. For the activity against *S. pyogenes*, the derivative **6a** was active with a MIC value of $90 \mu\text{g mL}^{-1}$, while the rest of the conjugates did not show significant activity as compared with standard Ciprofloxacin which had a MIC of $50 \mu\text{g mL}^{-1}$ (Fig. 2).

The novel indole dipeptide conjugate **6a–j** also displayed very good activity against invasive fungal strains. Conjugates **6g** and **6i** were most active against *C. albicans* at a MIC value of $50 \mu\text{g mL}^{-1}$ compared to Fluconazole which was active at $50 \mu\text{g mL}^{-1}$ (Table 1). Therefore, they were 2 times more effective than the standard drug against the *C. albicans*. Conjugates **6a** and **6d** also displayed good activity against *C. albicans* at a MIC value of $80 \mu\text{g mL}^{-1}$ and $100 \mu\text{g mL}^{-1}$, respectively. Other conjugates were found to be less active against *C. albicans* with MIC values $\geq 500 \mu\text{g mL}^{-1}$. When screened against the fungal strain *A. niger*, the conjugate **6d** was found to be most active at a MIC value of $50 \mu\text{g mL}^{-1}$ as compared to Fluconazole which was active against *A. niger* at $50 \mu\text{g mL}^{-1}$ (Table 1). It was 2 times more effective than

the standard drug against *A. niger*. Conjugates **6a** ($70 \mu\text{g mL}^{-1}$), **6g** ($80 \mu\text{g mL}^{-1}$), and **6i** ($80 \mu\text{g mL}^{-1}$) also displayed good inhibition against *A. niger* as compared to the control drug which had a MIC of $100 \mu\text{g mL}^{-1}$. However, other conjugates were found to be less active against *A. niger* with MIC values in a range of $\geq 500 \mu\text{g mL}^{-1}$ (Fig. 3).

4.3 Molecular docking

Crystal structure of DNA gyrase (PDB ID: 5BS8) and lanosterol 14-alpha demethylase (PDB ID: 4LXJ) are chosen from Protein Data Bank (PDB) based on the resolution quality parameter to perform binding affinity studies of indole derivatives.^{55,56} Many research groups have reported the application of indole-containing peptides as DNA gyrase inhibitors, along with the information on their synthesis, characterization, and biological evaluation. They described the design of new compounds, their inhibitory activity against DNA gyrase, and their potential as antimicrobial agents.^{57–60} Similarly, the design, synthesis, and biological evaluation of indole derivatives as inhibitors of lanosterol demethylase, a key enzyme in the biosynthesis of sterols in fungi, is also reported by many research groups. The studies showed that indole derivatives can inhibit the activity of this enzyme and have potential as antifungal agents.^{61–63} A protein preparation wizard was employed to repair both crystal structures by adding missing information such as adding hydrogens, assigning the right bond order, converting selenomethionine to methionine, and optimizing the orientation of hydroxyl and amine groups in serine (Ser), threonine (Thr), tyrosine (Tyr), and asparagine (Asn), glutamine (Gln), respectively.⁶⁴ Restrained minimization was performed using OPLS-3e forcefield.⁶⁵ Receptor grid generation was employed to generate the grid based on the centroid of the bound ligand in both enzyme crystal structures. The grid box was extended up to 15 \AA as the inner box and 20 \AA as the outer box covering the entire binding site. The 3D (three dimensional) builder module was employed to sketch the 10 indole derivative molecules followed by energy minimized to obtain the lowest energy state of ligands. Further,




Fig. 2 Antibacterial activity of the title compounds **6a–j**.






Fig. 3 Antifungal activity of the title compounds 6a–j.




Fig. 4 2D interaction diagram representation of ID-6c with DNA gyrase showing intermolecular interactions.



indole ligands were prepared using the LigPrep module to generate the proper ionization state of the ligand molecules at the default pH. Finally, prepared ligand molecules were docked in the generated grids in DNA gyrase and lanosterol 14- α demethylase using the extra precision (XP) docking protocol. Each of the poses was analysed for intermolecular interactions, Glide docking, and Glide emodel score.

4.4 Molecular dynamics (MD) simulation

MD simulation was used to assess the conformational changes and stability of the target proteins (DNA gyrase and lanosterol 14- α demethylase) in the presence of the test compound **6c**. An MD simulation study was carried out using the Desmond module of the Schrödinger 2021-1 suite, which has been run on an Ubuntu 18.04 HP Z2 G2 TOWER workstation integrated with an NVIDIA Quadro 6000 graphics processing unit (GPU).^{66,67} The docked ligand-protein complex of compound **6c** was chosen, and the system was modelled using a preset solvent system of SPC water molecules with orthorhombic boundary conditions. Counter-ions (Na^+ and Cl^-) were added to neutralize the simulation box, the constructed system was submitted to energy

minimization until a gradient threshold of 1 kcal mol^{-1} was obtained at 300 K and 1 bar of pressure using the *NPT* (N = number of particles, P = pressure, and T = temperature) (isothermal-isobaric) ensemble class.⁶⁸⁻⁷¹ Lastly, both systems of compound **6c** with DNA gyrase and lanosterol 14- α demethylase were subjected to a production run for 100 ns with a time step of 100 ps under *NPT* ensemble conditions.

4.5 DNA gyrase binding study

Molecular docking studies of the indole derivatives **6a-j** were performed on DNA gyrase and lanosterol 14- α demethylase to study their binding poses, intermolecular interactions, and binding strength of indole derivatives (Fig. 4-8 and S1-S15†). The indole derivative **6c** (**ID-6c**) displayed a reasonable number of interactions with the DNA gyrase enzyme. The benzene moiety of **ID-6c** showed π - π stacking interaction with DNA nucleotide 'adenine' however, Lys441, Asp461, and Ptr129 residues displayed hydrogen bond interaction networks with ligand molecules as shown in Fig. 4. The computed binding affinity of **ID-6c** was found to be $-7.8 \text{ kcal mol}^{-1}$. The Glide emodel was calculated to be -101.1 for the **ID-6c** molecule.




Fig. 5 2D interaction diagram representation of ID-6h with DNA gyrase showing intermolecular interactions.



Whereas **ID-6h** ligand molecule also projected a good amount of intermolecular interaction networks with DNA gyrase as shown in Fig. 5. The benzene moiety of **ID-6h** ligand displayed π - π stacking interaction with the pyrimidine moiety of DT 10 and DA base of DNA. It also displayed π -cation interaction with Arg482. The other important residues such as Ptr129 and DA displayed hydrogen bond interaction with a ligand molecule. The binding affinity of **ID-6h** was computed to be $7.7 \text{ kcal mol}^{-1}$. The calculated Glide emodel score of **ID-6h** was found to be -106.9 which is slightly better than the **ID-6c** molecule.

Further, we have compared the results with the standard drug ciprofloxacin. Ciprofloxacin (quinolone ring) showed π - π stacking interaction with DNA nucleotide adenine-15 and guanine-11, whereas the carboxylic acid group established the hydrogen bond and salt bridge interaction with the Arg-128 as shown in Fig. 6. The overall docking study highlighted that indole derivatives are comfortably binding in the quinolone binding pocket (QBP) by forming interaction networks with Arg482, Tyr129, DT10, and DA11 majorly. All the calculated docking energy parameters of indole derivatives **6a-j** are listed in Table 2.

4.6 Lanosterol 14-alpha demethylase binding study

In the case of lanosterol 14-alpha demethylase (CYP51), the **ID-6c** molecule displayed very good binding strength due to a greater number of intermolecular interactions. The binding poses of **ID-6c** projected hydrogen bond interaction networks with Arg98, Phe241, His381, Ser382, and Ser504 residues. The

Table 2 Various docking energy parameters of indole derivatives with DNA gyrase

Molecule ID	Docking score (kcal mol ⁻¹)	Glide emodel
ID-6c	-7.8	-101.1
ID-6f	-7.8	-96.9
ID-6h	-7.7	-106.9
ID-6g	-7.7	-100.2
ID-6b	-7.5	-88.1
ID-6a	-6.9	-103.8
ID-6d	-6.8	-94.3
ID-6j	-6.8	-85
ID-6i	-6.5	-86.2
Ciprofloxacin	-9.475	-89.761

benzene moieties of the ligand molecule also displayed π - π stacking interaction networks with Tyr126 and Phe241 as shown in Fig. 7. The computed binding affinity of **ID-6c** was found to be $-12.8 \text{ kcal mol}^{-1}$ and the Glide emodel score was calculated to be -130.5 . From the docking study, it is understood that indole derivatives are comfortably binding to the enzyme by making hydrogen bonds and π - π stacking interactions with active site residues. These results were compared with the standard drug fluconazole, which showed the π - π stacking interactions with the Phe-236 with docking score of the $-6.913 \text{ kcal mol}^{-1}$ as shown in Fig. 8. Overall, binding poses and interaction networks of indole molecules revealed that Tyr126, Tyr129, Phe241, His381, Ser382, and Met509 residues are vital for binding. The calculated various docking energy




Fig. 6 2D interaction diagram representation of Ciprofloxacin with DNA gyrase showing intermolecular interactions.






Fig. 7 2D interaction diagram representation of ID-6c with lanosterol 14-alpha demethylase showing intermolecular interactions.




Fig. 8 2D interaction diagram representation of Fluconazole with lanosterol 14-alpha demethylase showing intermolecular interactions.



Table 3 Various docking energy parameters of indole derivatives with lanosterol 14- α demethylase

Molecule ID	Docking score (kcal mol ⁻¹)	Glide emodel
ID-6c	-12.8	-130.5
ID-6d	-12.4	-115.3
ID-6e	-12.1	-129.3
ID-6i	-12	-124.5
ID-6f	-10.9	-112
ID-6j	-10.8	-116.3
ID-6a	-10.1	-136.2
ID-6h	-9.7	-121.7
ID-6b	-9.6	-109.2
ID-6g	-9.6	-123
Fluconazole	-6.913	-62.202

parameters of indole derivatives with lanosterol 14- α demethylase are listed in Table 3.

4.7 Molecular insights from MD simulations

In molecular docking study of all the compounds it was seen that compound **6c** exhibited the highest docking score towards the DNA gyrase and lanosterol 14- α demethylase, while compound **6g** demonstrated significant antibacterial activity. Therefore, considering the docking score as a determining factor, compound **6c** was subsequently chosen for further simulation. The Desmond Simulation Package was used to run MD simulations for 100 ns following the docking calculations to assess the steady nature and conformational stability of compound **6c** in complex with DNA gyrase and lanosterol 14- α demethylase. The MDS trajectories have been used to calculate the root-mean square deviation (RMSD) of the ligand, the RMSD of protein C α atoms, the root-mean square

fluctuation (RMSF) of protein amino acids, and a histogram indicating ligand–protein interactions of the complexes in order to explore their structural stabilities, and binding modes. Total structural changes of protein–ligand complexes were initially investigated in terms of RMSD in the coordinates of protein C α atoms and ligand from the original docked conformation. It was observed that when compound **6c** is in the system, the maximum RMSD values of protein and ligand were ~ 3.6 Å and ~ 4.9 Å, respectively. The C α atoms of GyrB were found to fluctuate slightly, while in the ligand a mean RMSD of ~ 2.2 Å was observed for the duration between 0 and 72 ns, after which drift and fluctuation could be observed from 72 to 76 ns and remained stable till 100 ns. Fig. 9A demonstrated clearly that the compound **6c-5BS8** systems were consistent in sustaining the molecular interaction profile throughout the simulation run and, more importantly, did not exhibit significant fluctuation, which is an absolutely acceptable range for judging the protein–ligand complex interaction stability. Similarly, the RMSD plot of the **6c-4LXJ** complex shows initial fluctuation during ~ 0 –29 ns with an average RMSD of ~ 3.8 Å. With slight drift, RMSD increased to ~ 4.9 Å at ~ 32 ns, after minor fluctuation was observed, and a stable equilibrium was continued for the remaining period of simulation. However, the ligand plot shows an initial fluctuation due to equilibration and remains consistent around the RMSD value of ~ 3.6 Å till 100 ns (Fig. 10A). From the above data, it is clear that the C α atoms of DNA gyrase and lanosterol 14- α demethylase bound with compound **6c** remained stable during the simulation.

To assess the flexibility of the residues, the individual amino acid based RMSF in the trajectory was computed. More flexibility during the MD simulation is shown by higher RMSF values. The findings reveal that the RMSF of the protein molecule varies in different areas of the protein. Protein secondary structural elements, such as α -helical and β -strand, are




Fig. 9 MD simulation analysis of **6c** in complex with DNA gyrase (PDB ID: 5BS8) (A) time dependent RMSD of **6c-5BS8** complex (protein C α -atoms RMSD is shown in grey while RMSD of compound **6c** with respect to protein are shown in red) (B) protein amino acids RMSF (C) ligand 2d interaction diagram and (D) protein–ligand contact histogram obtained from MD trajectory.






Fig. 10 MD simulation analysis of **6c** in complex with lanosterol 14- α demethylase (PDB ID: 4LXJ) (A) time dependent RMSD of **6c**-LXJ complex (protein C α -atoms RMSD is shown in grey while RMSD of compound **6c** with respect to protein are shown in red) (B) protein amino acids RMSF (C) ligand 2d interaction diagram and (D) protein–ligand contact histogram obtained from MD trajectory.

displayed in red and blue backgrounds, respectively, in the RMSF plot, whereas the loop region is portrayed in white shades. Excluding the loop areas and the N/C terminus, the values of most residues are less than 2 Å, indicating that the residue conformation is relatively consistent during the simulation illustrated in Fig. 9B and 10B. The RMSF plot also showed that in the **6c**-5BS8 complex, 25 amino acids interacted with the ligand, while in the **6c**-4LXJ complex, 30 amino acids interacted with the ligand. All of these interacting residues are marked by a green vertical line. The average RMSF was found to be 1.14 Å and 1.7 Å in the case compound **6c** was bound with DNA gyrase and lanosterol 14- α demethylase protein, respectively. The low values observed undoubtedly revealed that there was an insignificant fluctuation in any interacted amino acid residues during the simulation. In the **6c**-5BS8 complex, ligand 2d interaction showed that indole moiety interacted with Tyr93 through π - π stacking at 11% of simulation time.

Through amino acid mediated hydrogen bonding and direct hydrogen bonding, compound **6c**'s terminal hydroxyl group formed H-bonds with lys441, pro123, and asp122 amino acid residues (Fig. 9C). The phenyl ring of the indole scaffold showed 44% simulation trajectories of parallel π - π stacking with the hydrophobic amino acid Phe241, while the NH group interacted with Ser308 and Tyr72 via amino acid mediated hydrogen bonding in the case of the **6c**-4LXJ complex. In this complex, one ionic interaction is observed between the hydroxyl group and Cys470 through the protein Fe ion. In particular, polar amino acids His381, and Ser382 are involved in notable hydrogen bonding with the compound **6c** at 74% and 43% of the simulation time, respectively (Fig. 10C).

The simulation interaction diagram can be used to study the four types of protein–ligand interactions (hydrogen bonds, hydrophobic interactions, ionic interactions, and water bridge

interactions) that occurred throughout the 100 ns MD simulation study. The interactions in **6c**-5BS8 and **6c**-4LXJ complexes are given in Fig. 9D and 10D. It can be observed that compound **6c** formed major amino acid mediated hydrogen bonding, followed by hydrophobic interactions with several amino acids of the catalytic site cavity of DNA gyrase. While in lanosterol 14- α demethylase protein, compound **6c** is stabilized by crucial hydrogen bonding and hydrophobic interaction. In particular, the significant polar contacts and particular hydrogen bond interactions (>30% of occupancy) were higher in **6c**-4LXJ than in **6c**-5BS8.

5 Conclusion

In this research article, a new library of hybrids of peptide-heterocycle consisting of indole-3-carboxylic acid constituent conjugated with short dipeptide motifs was outlined and prepared by using the methodology of solid phase peptide synthesis. All the synthesized compounds were characterized by elemental analysis and techniques of spectroscopy. Also, *in vitro* antimicrobial activities of the synthesized peptides were studied with the anticipation of finding out new therapeutics with potent antimicrobial properties. On analysing against Ciprofloxacin, the standard drug, derivatives **6a**, **6d**, **6g**, and **6i** demonstrated better activities versus bacterial strains. Compound **6g** demonstrated excellent activity versus both bacterial and fungal species. It was evident from the findings that on incorporating methionine into the peptide chain, the microbial activities versus both bacterial and fungal strains have remarkably surged. Molecular docking studies of synthesized compounds against DNA GyrB and lanosterol 14- α demethylase exhibited a correlation between the docking score and biological activities. The 100 ns MD study investigations on



compound **6c** complex with DNA GyrB and lanosterol 14-alpha demethylase displayed that both complexes attain stability of interaction networks and conformational flexibilities. The obtained results from the current research aid to elucidate further advancement of antimicrobial agents consisting of hybrids of peptide-heterocycle.

Conflicts of interest

The authors declare no conflicts of interest regarding the publication of this paper.

Acknowledgements

The authors are thankful to the University Grants Commission, New Delhi, and Marwadi University, for technical and academic support. The authors are also thankful to the Department of Pharmacoinformatics, NIPER, Mohali, for providing Molecular docking studies report and Indrashil University, Kadi, Gujarat, for providing spectral data, also, Dr Ramesh Chandra Gupta (Banaras Hindu University) for his guidance throughout this project.

References

- 1 A. C. Singer, H. Shaw, V. Rhodes and A. Hart, *Front. Microbiol.*, 2016, **7**, 1728.
- 2 B. M. Marshall and S. B. Levy, *Clin. Microbiol. Rev.*, 2011, **24**, 718–733.
- 3 J. O'Neill, Tackling drug-resistant infections globally: final report and recommendations, *Review on Antimicrobial Resistance*, London, 2016.
- 4 WHO, *Antimicrobial resistance*, accessed Jan 08, 2023, 2021, <https://www.who.int/newsroom/factsheets/detail/antimicrobial-resistance>.
- 5 F. Prestinaci, P. Pezzotti and A. Pantosti, *Pathog. Global Health*, 2015, **109**, 309–318.
- 6 B. Aslam, W. Wang, M. I. Arshad, M. Khurshid, S. Muzammil, M. H. Rasool, M. A. Nisar, R. F. Alvi, M. A. Aslam, M. U. Qamar, M. K. F. Salamat and Z. Baloch, *Infect. Drug Resist.*, 2018, **11**, 1645–1658.
- 7 S. B. Zaman, M. A. Hussain, R. Nye, V. Mehta, K. T. Mamun and N. Hossain, *Cureus*, 2017, **9**, e1403.
- 8 M. Mahlapuu, J. Håkansson, L. Ringstad and C. Björn, *Front. Cell. Infect. Microbiol.*, 2016, **6**, 194.
- 9 K. K. Sharma, R. Ravi, I. K. Maurya, A. Kapadia, S. I. Khan, V. Kumar, K. Tikoo and R. Jain, *Eur. J. Med. Chem.*, 2021, **223**, 113635–113650.
- 10 K. K. Sharma, I. K. Maurya, S. I. Khan, M. R. Jacob, V. Kumar, K. Tikoo and R. Jain, *J. Med. Chem.*, 2017, **60**, 6607–6621.
- 11 S. R. Tivari, S. V. Kokate, E. M. Sobhia, S. G. Kumar, U. B. Shelar and Y. S. Jadeja, *ChemistrySelect*, 2022, **7**(27), e202201481.
- 12 C. T. Mant, Z. Jiang, L. Gera, T. Davis, K. L. Nelson, S. Bevers and R. S. Hodges, *J. Med. Chem.*, 2019, **67**(7), 3354–3366.
- 13 N. Mookherjee, M. A. Anderson, H. P. Haagsman and D. J. Davidson, *Nat. Rev. Drug Discovery*, 2020, **19**, 311–332.
- 14 B. Mishra, S. Reiling, D. Zarena and G. Wang, *Curr. Opin. Chem. Biol.*, 2017, **38**, 87–96.
- 15 S. R. Dennison, M. Mura, F. Harris, L. H. G. Morton, A. Zvelindovsky and D. A. Phoenix, *Biochim. Biophys. Acta, Biomembr.*, 2015, **1848**, 1111–1118.
- 16 M. Zheng, M. Pan, W. Zhang, H. Lin, S. Wu, C. Lu, S. Tang, D. Liu and J. Cai, *Bioact. Mater.*, 2021, **6**(7), 1878–1909.
- 17 Yolandani, H. Ma, Y. Li, D. Liu, H. Zhou, X. Liu, Y. Wan and X. Zhao, *Ultrason. Sonochem.*, 2023, **95**, 106414.
- 18 Y. Xie, T. L. Lopez-Silva and J. P. Schneider, *Org. Lett.*, 2022, **24**(40), 7378–7382.
- 19 I. Lace, E. R. Cotroneo, N. Hesselbarth and N. A. Simeth, *J. Pept. Sci.*, 2023, **29**, e3466.
- 20 C. An, S. Wei, Y. Dao, X. Wang, W. Dong, X. You, C. Tian, Z. Zhang and S. Dong, *Bioorg. Chem.*, 2023, **134**, 106424.
- 21 S. Reardon, *Nature*, 2015, **521**, 402–403.
- 22 X. Bao, K. Qian, M. Xu, Y. Chen, H. Wang, T. Pan, Z. Wang, P. Yao and L. Lin, *J. Nanobiotechnol.*, 2023, **21**, 16.
- 23 S. Maher, R. J. Mrsny and D. J. Brayden, *Adv. Drug Delivery Rev.*, 2016, **106**, 277–319.
- 24 J. D. Steckbeck, B. Deslouches and R. C. Montelaro, *Expert Opin. Biol. Ther.*, 2014, **14**, 11–14.
- 25 W. M. Hewitt, S. S. Leung, C. R. Pye, A. R. Ponkey, M. Bednarek, M. P. Jacobson and R. S. Lokey, *J. Am. Chem. Soc.*, 2015, **137**, 715–721.
- 26 S. R. Tivari, S. V. Kokate, U. B. Shelar and Y. S. Jadeja, *Rasayan J. Chem.*, 2022, **15**(2), 875–884.
- 27 S. R. Tivari, S. V. Kokate, M. S. Gayke, I. Ahmad, H. Patel, S. G. Kumar and Y. S. Jadeja, *ChemistrySelect*, 2022, **7**(48), e202203462.
- 28 J. M. Palomo, *RSC Adv.*, 2014, **4**, 32658–32672.
- 29 Y. N. Mabkhot, F. Alatibi, N. N. E. El-Sayed, S. Al-Showiman, N. A. Kheder, A. Wadood, A. Rauf, S. Bawazeer and T. B. Hadda, *Molecules*, 2016, **21**(2), 222.
- 30 N. B. Perry, J. W. Blunt and M. H. Munro, *Tetrahedron*, 1988, **44**, 1727–1734.
- 31 J. I. Kobayashi, J. F. Cheng, M. Ishibashi, H. Nakamura, Y. Ohizumi, Y. Hirata, T. Sasaki, H. Lu and J. Clardy, *Tetrahedron Lett.*, 1987, **28**, 4939–4942.
- 32 M. Al-Smadi and F. Al-Momani, *Molecules*, 2008, **13**, 2740–2749.
- 33 S. Tivari, S. V. Kokate, U. B. Shelar and Y. Jadeja, *Rasayan J. Chem.*, 2022, **15**(2), 875–884.
- 34 M. V. Raimondi, A. Presentato, G. L. Petri, M. Buttacavoli, A. Ribaud, V. de Caro, R. Alduina and P. Cancemi, *Antibiotics*, 2020, **9**, 292.
- 35 M. V. Raimondi, R. Listro, M. G. Cusimano, M. la Franca, T. Faddetta, G. Gallo, D. Schillaci, S. Collina, A. Leonchiks and G. Barone, *Bioorg. Med. Chem.*, 2019, **27**, 721–728.
- 36 V. Spanò, R. Rocca, M. Barreca, D. Giallombardo, A. Montalbano, A. Carbone, M. V. Raimondi, E. Gaudio, R. Bortolozzi, R. Bai, P. Tassone, S. Alcaro, E. Hamel, G. Viola, F. Bertoni and P. Barraja, *J. Med. Chem.*, 2020, **63**, 12023–12042.
- 37 S. Xue, L. Ma, R. Gao, Y. Lin and Z. Linn, *Acta Pharm. Sin. B*, 2014, **4**, 313–321.



- 38 K. S. Prasad, R. R. Pillai, M. P. Ghimire, R. Ray, M. Richter, C. Shivamallu, A. S. Jain, S. K. Prasad, P. Sushma, S. Armaković, S. J. Armaković and R. G. Amachawadi, *J. Mol. Struct.*, 2020, **1217**, 128445.
- 39 A. Ozdemir, M. D. Altıntop, G. T. Zitouni, G. A. Çiftçi, I. Ertorun, O. Alatas and Z. A. Kaplancıklı, *Eur. J. Med. Chem.*, 2015, **89**, 304–309.
- 40 H. M. Kasralikar, S. C. Jadhavar and S. R. Bhusare, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 3882–3886.
- 41 H. Gurer-Orhan, C. Karaaslan, S. Ozcan, O. Firuzi, M. Tavakkoli, L. Saso and S. Suzen, *Bioorg. Med. Chem.*, 2016, **24**, 1658–1664.
- 42 W. Hong, J. Li, Z. Chang, X. Tan, H. Yang, Y. Ouyang, Y. Yang, S. Kaur, I. C. Paterson, Y. F. Ngeow and H. Wang, *J. Antibiot.*, 2017, **70**, 832–844.
- 43 V. Velezheva, P. Brennan, P. Ivanov, A. Kornienko, S. Lyubimov, K. Kazarian, B. Nikonenko, K. Majorov and A. Apt, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 978–985.
- 44 J. A. Generali and D. J. Cada, *Hosp. Pharm.*, 2009, **44**, 670–671.
- 45 R. Horton, *Lancet*, 2001, **357**, 1544–1545.
- 46 S. H. Ferreira, S. Moncada and J. R. Vane, *Nature (London), New Biol.*, 1971, **231**, 237–239.
- 47 K. E. Andersson, *Pharmacol. Rev.*, 2001, **53**, 417–450.
- 48 D. M. M. Jaradat, *Amino Acids*, 2017, **50**, 39–68.
- 49 V. Made, S. Els-Heindl and A. G. Beck-Sickinger, *Beilstein J. Org. Chem.*, 2014, **10**, 1197–1212.
- 50 E. Kaiser, R. L. Colescott, C. D. Bossinger and P. I. Cook, *Anal. Biochem.*, 1970, **34**(2), 595–598.
- 51 R. Behrendt, P. White and J. Offer, *J. Pept. Sci.*, 2016, **22**, 4–27.
- 52 N. C. Desai, K. A. Jadeja, D. J. Jadeja, V. M. Khedkar and P. C. Jha, *Synth. Commun.*, 2021, **51**(6), 952–963.
- 53 B. Kowalska-Krochmal and R. Dudek-Wicher, *Pathogens*, 2021, **10**(2), 165.
- 54 J. H. Jorgensen and M. J. Ferraro, *Clin. Infect. Dis.*, 2009, **49**, 1749–1755.
- 55 T. R. Blower, B. H. Williamson, R. J. Kerns and J. M. Berger, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**(7), 1706–1713.
- 56 B. C. Monk, T. M. Tomasiak, M. V. Keniya, F. U. Huschmann, J. D. Tyndall, J. D. O'Connell, R. D. Cannon, J. G. McDonald, A. Rodriguez, J. S. Finer-Moore and R. M. Stroud, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**(10), 3865–3870.
- 57 M. A. Salem, A. Ragab, A. El-Khalafawy, A. H. Makhlof, A. A. Askar and Y. A. Ammar, *Bioorg. Chem.*, 2020, **96**, 103619.
- 58 H. Liu, Z.-W. Chu, D.-G. Xia, H.-Q. Cao and X.-H. Lv, *Bioorg. Chem.*, 2020, **99**, 103807.
- 59 Y. Hu, H. Shi, M. Zhou, Q. Ren, W. Zhu, W. Zhang, Z. Zhang, C. Zhou, Y. Liu, X. Ding, H. C. Shen, S. F. Yan, F. Dey, W. Wu, G. Zhai, Z. Zhou, Z. Xu, Y. Ji, H. Lv, T. Jiang, W. Wang, Y. Xu, M. Vercrusse, X. Yao, Y. Mao, X. Yu, K. Bradley and X. Tan, *J. Med. Chem.*, 2020, **63**(17), 9623–9649.
- 60 M. A. Salem, A. Ragab, A. A. Askar, A. El-Khalafawy and A. H. Makhlof, *Eur. J. Med. Chem.*, 2020, **188**, 111977.
- 61 Pooja, P. Prasher, P. Singh, K. Pawar, K. S. Vikramdeo, N. Mondal and S. S. Komath, *Eur. J. Med. Chem.*, 2014, **80**, 325–339.
- 62 A. Angarita-Rodríguez, D. Quiroga and E. Coy-Barrera, *Molecules*, 2019, **25**(1), 45.
- 63 P. Singh, P. Verma, B. Yadav and S. S. Komath, *Bioorg. Med. Chem. Lett.*, 2011, **21**(11), 3367–3372.
- 64 G. M. Sastry, M. Adzhigirey, T. Day, R. Annabhimoju and W. Sherman, *J. Comput.-Aided Mol. Des.*, 2013, **27**(3), 221–234.
- 65 K. Roos, C. Wu, W. Damm, M. Reboul, J. M. Stevenson, C. Lu, M. K. Dahlgren, S. Mondal, W. Chen, L. Wang and R. Abel, *J. Chem. Theory Comput.*, 2019, **15**(3), 1863–1874.
- 66 R. Pawara, I. Ahmad, S. Surana and H. Patel, *In Silico Pharmacol.*, 2021, **6**(1), 54.
- 67 K. J. Bowers, D. E. Chow, H. Xu, R. O. Dror, M. P. Eastwood, B. A. Gregersen, J. L. Klepeis, I. Kolossvary, M. A. Moraes, F. D. Sacerdoti, J. K. Salmon, Y. Shan and D. E. Shaw, *Proceedings of the 2006 ACM/IEEE Conference on Supercomputing*, IEEE, 2006, p. 43.
- 68 W. L. Jorgensen, D. S. Maxwell and J. Tirado-Rives, *J. Am. Chem. Soc.*, 1996, **118**(45), 11225–11236.
- 69 R. Girase, I. Ahmad, R. Pawara and H. Patel, *SAR QSAR Environ. Res.*, 2022, **33**(3), 1–21.
- 70 G. Kalibaeva, M. Ferrario and G. Ciccotti, *Mol. Phys.*, 2003, **101**(6), 765–778.
- 71 G. J. Martyna, *Phys. Rev. E*, 1994, **50**(4), 3234–3236.

